4552 Stock Overview
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
JCR Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥856.00 |
52 Week High | JP¥1,567.00 |
52 Week Low | JP¥842.00 |
Beta | -0.00075 |
1 Month Change | -7.66% |
3 Month Change | -26.96% |
1 Year Change | -44.13% |
3 Year Change | -76.06% |
5 Year Change | -42.06% |
Change since IPO | 284.72% |
Recent News & Updates
JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Mar 18JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
Feb 29Shareholder Returns
4552 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -3.8% | 0.2% | 1.7% |
1Y | -44.1% | 16.5% | 37.6% |
Return vs Industry: 4552 underperformed the JP Pharmaceuticals industry which returned 16.5% over the past year.
Return vs Market: 4552 underperformed the JP Market which returned 37.6% over the past year.
Price Volatility
4552 volatility | |
---|---|
4552 Average Weekly Movement | 4.7% |
Pharmaceuticals Industry Average Movement | 3.8% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.4% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4552's share price has been volatile over the past 3 months.
Volatility Over Time: 4552's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1975 | 879 | Shin Ashida | https://www.jcrpharm.co.jp |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.
JCR Pharmaceuticals Co., Ltd. Fundamentals Summary
4552 fundamental statistics | |
---|---|
Market cap | JP¥108.83b |
Earnings (TTM) | JP¥5.36b |
Revenue (TTM) | JP¥41.37b |
19.9x
P/E Ratio2.6x
P/S RatioIs 4552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4552 income statement (TTM) | |
---|---|
Revenue | JP¥41.37b |
Cost of Revenue | JP¥10.41b |
Gross Profit | JP¥30.96b |
Other Expenses | JP¥25.59b |
Earnings | JP¥5.36b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
Earnings per share (EPS) | 42.98 |
Gross Margin | 74.83% |
Net Profit Margin | 12.97% |
Debt/Equity Ratio | 41.6% |
How did 4552 perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield47%
Payout RatioDoes 4552 pay a reliable dividends?
See 4552 dividend history and benchmarksJCR Pharmaceuticals dividend dates | |
---|---|
Ex Dividend Date | Mar 28 2024 |
Dividend Pay Date | Jun 24 2024 |
Days until Ex dividend | 1 day |
Days until Dividend pay date | 87 days |
Does 4552 pay a reliable dividends?
See 4552 dividend history and benchmarks